Rhumbline Advisers Atreca, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.56 - $3.25 $47,360 - $98,666	-30,359 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.61 - $5.2 $6,541 - $21,127	-4,063 Reduced 11.8%	30,359 $96,000
Q4 2021 Feb 10, 2022	SELL	$2.87 - $6.29 $1,541 - $3,377	-537 Reduced 1.54%	34,422 $104,000
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $4,094 - $7,564	834 Added 2.44%	34,959 $218,000
Q2 2021 Aug 05, 2021	BUY	$7.82 - $13.8 $48,405 - $85,422	6,190 Added 22.16%	34,125 $291,000
Q1 2021 May 06, 2021	SELL	$13.0 - $19.34 $18,395 - $27,366	-1,415 Reduced 4.82%	27,935 $428,000
Q4 2020 Feb 10, 2021	BUY	$13.03 - $17.09 $44,888 - $58,875	3,445 Added 13.3%	29,350 $474,000
Q3 2020 Nov 12, 2020	BUY	$12.67 - $23.19 $7,627 - $13,960	602 Added 2.38%	25,905 $362,000
Q2 2020 Aug 13, 2020	BUY	$12.52 - $23.45 $111,741 - $209,291	8,925 Added 54.49%	25,303 $538,000
Q1 2020 May 06, 2020	BUY	$11.4 - $27.28 $186,709 - $446,791	16,378 New	16,378 $271,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.